CEL-SCI Corporation (NYSE Amex: CVM) announced today that it has fully paid off its outstanding convertible debenture. The Company had been making monthly payments of approximately $1 million per month to repay a $9 million convertible debenture which CEL-SCI had issued in connection with the settlement of litigation. CEL-SCI has now eliminated the convertible debenture and any associated preferential rights. “We are pleased that we have eliminated this substantial obligation and the associated potential dilution,” said Geert Kersten, Chief Executive Officer of CEL-SCI. “Our money is now being allocated to the greatest benefit of our shareholders, namely an expansion of our Phase III study by adding 10-15 additional clinical sites in four more countries.” About CEL-SCI Corporation CEL-SCI is dedicated to research and development directed at improving the treatment of cancer and other diseases by utilizing the immune system, the body's natural defense system. Its lead investigational therapy is Multikine (Leukocyte Interleukin, Injection), currently being studied in a pivotal global Phase III clinical trial. CEL-SCI is also developing (and investigating) an immunotherapy (LEAPS-H1N1-DC) as a possible treatment for H1N1 hospitalized patients and as a vaccine (CEL-2000) for Rheumatoid Arthritis (currently in preclinical testing) using its LEAPS technology platform. The investigational immunotherapy LEAPS-H1N1-DC treatment involves non-changing regions of H1N1 Pandemic Flu, Avian Flu (H5N1), and the Spanish Flu, as CEL-SCI scientists are very concerned about the possible emergence of a new more virulent hybrid virus through the combination of H1N1 and Avian Flu, or maybe Spanish Flu. The Company has operations in Vienna, Virginia, and in/near Baltimore, Maryland. For more information, please visit www.cel-sci.com.